PD-1 blockage as consolidation therapy after autologous stem cell transplant in patients with T-cell non-Hodgkin’s lymphoma shows improvements in progression-free survival
Low CD30 Expression in Non-Hodgkin’s Lymphoma Patients Does Not Predict Low Response to Brentuximab Vedotin
Low CD30 expression in non-Hodgkin’s lymphoma patients does not predict low response to brentuximab vedotin, shows new study.
In Search of Targeted Therapies for T-Cell Lymphoma
Developing treatments for T-cell lymphoma has been challenging due to the limited number of study participants and an inability to identify the molecular pathways leading to the disease. Cleveland Clinic investigators are involved in several projects intended to increase treatment options.